Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Sales

Intellia Therapeutics (NTLA) EBIT Margin (2016 - 2026)

Intellia Therapeutics has reported EBIT Margin over the past 12 years, most recently at 668.08% for Q1 2026.

  • Quarterly EBIT Margin rose 5850.0% to 668.08% in Q1 2026 from the year-ago period, while the trailing twelve-month figure was 636.56% through Mar 2026, up 55080.0% year-over-year, with the annual reading at 651.67% for FY2025, 27143.0% up from the prior year.
  • EBIT Margin was 668.08% for Q1 2026 at Intellia Therapeutics, down from 428.86% in the prior quarter.
  • Over five years, EBIT Margin peaked at 7297.44% in Q4 2023 and troughed at 1998.61% in Q2 2024.
  • The 5-year median for EBIT Margin is 808.86% (2025), against an average of 452.5%.
  • Year-over-year, EBIT Margin soared 2320217bps in 2022 and then tumbled -835731bps in 2024.
  • A 5-year view of EBIT Margin shows it stood at 811.07% in 2022, then skyrocketed by 1000bps to 7297.44% in 2023, then plummeted by -115bps to 1059.86% in 2024, then surged by 60bps to 428.86% in 2025, then tumbled by -56bps to 668.08% in 2026.
  • Per Business Quant, the three most recent readings for NTLA's EBIT Margin are 668.08% (Q1 2026), 428.86% (Q4 2025), and 808.86% (Q3 2025).